🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“OK, let’s not reinvent the wheel…” So much in this Tom Standage book on the literally thousands of years between someone ‘inventing’ the wheel, people mostly not caring, and more widespread uptake. And you think selling your AI solution to pharma takes time…? 😅

First time my Starlink has let me down - Elon Musk, could it at least have some warning built in? The app is like a bad Apple app - just spinning fruitlessly - unable to 'find' a satellite...

Very excited - we’ve almost filled our 2025 target for the Virtual Chief Commercial Officer cohort of 15 biotechs… (Keeping it manageable while we learn exactly what is wanted) This is the future of biotech commercial 🤘🏻 Early enough to help direct valuable commercial

Biotech2k $CADL Viral immunotherapy. Pipeline in a product for 2 assets CAN-2409 and CAN-3110. Huge unmet needs in all indications such as Early localized prostate cancer with recent stat sig Phase 3 data done under SPA. Phase 2 NSCLC after failing chemo & ICI. Pancreatic & HGG

What do we mean when we say “let’s not reinvent the wheel…” Targeting new medicines at what physicians will prescribe in 15 years, requires decision systems that increase the importance of those parameters, instead of fitness for pI, pII, pIII hurdles... ideapharma.substack.com/p/inventing-an…

I have to move my hifi around fairly often (my wife…) and I don't think I've ever wired it up and had it work first time 😬😖 Kind of long for the simplicity of these old fellas 😅

This reminds me of a McK forecast in pre-launch - 'we were right, but the market didn't play ball…' 😅 (German news…)

Excited to see that Urology Times covered the FDA's RMAT designation for CAN-2409 in localized prostate cancer! RMAT validates the critical unmet need in early-stage prostate cancer and supports our phase 3 study design. urologytimes.com/view/fda-award… $CADL

Within the new podcast series - planning to restart the Pharma Book Club, now that I'm reading again... Check out what's there - folks like Vinay Prasad MD MPH, Annie Duke, Peter Kolchinsky, Matt Ridley, Steven Johnson, Katherine Eban and more... youtube.com/playlist?list=…

$CF Candel Therapeutics to share company update at Canaccord Genuity Growth Conference tinyurl.com/2xjjl6rb #CF

ASCO Daily covered CAN-2409's long-term benefits in localized prostate cancer. 30% improvement in disease-free survival with a generally good safety profile -a potential breakthrough for ~55K men/year in the US who elect to undergo RT with curative intent. dailynews.ascopubs.org/do/can-2409-vi…

New Symbol Soup single out everywhere (?) open.spotify.com/track/0lAcU9RM…

Does being better at prediction help your predictions? Why pharma's decision-making processes need to change...

We're developing CAN-2409 for patients with non-small cell lung cancer (NSCLC). Our phase 2a data in advanced NSCLC with an inadequate response to immune checkpoint inhibitors showed 24.5 mos. median OS vs published data in this population of 9.8-11.8 mos. with standard chemo.

I caught up with John Maraganore 🇺🇸🇬🇷🇺🇦🇮🇱 earlier today and asked him for some quick advice for biotech CEOs navigating this tough environment: John: Take a step back and really think about what's important for patients and value creation. But start with patients. And typically, if you

Amazing story about how intensely Lincoln studied Euclid's "Elements" to find out the precise meaning of the word 'demonstrate'.

"As the dust settles, questions pop up. Developing GLP-1 drugs was hard but didn't require alien-level tech. The more people reflect, the more comments surface suggesting that one of the biggest barriers was cultural: to many, obesity was a choice rather than a disease"

I guess not moving at all is a pretty decent signal of poor outcomes…

Pharma looks at this, and dreams of 54% 😅

Imagine telling folks at Pfizer about this, even 10 years ago